These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 1442812)

  • 21. Disease, drugs, and delay: suggested changes for the FDA.
    Petricciani JC
    Clin Res; 1990 Dec; 38(4):701-3. PubMed ID: 2276258
    [No Abstract]   [Full Text] [Related]  

  • 22. Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
    Fed Regist; 1998 May; 63(91):26191-3. PubMed ID: 10179336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA, off-label use, and informed consent: debunking myths and misconceptions.
    Beck JM; Azari ED
    Food Drug Law J; 1998; 53(1):71-104. PubMed ID: 11795338
    [No Abstract]   [Full Text] [Related]  

  • 24. Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.
    Riner A; Chan-Tack KM; Murray JS
    Postgrad Med; 2009 May; 121(3):139-46. PubMed ID: 19491552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant FDA approvals in 1997.
    Rheinstein PH; Akbari B
    Am Fam Physician; 1998 Jun; 57(11):2865-8. PubMed ID: 9636343
    [No Abstract]   [Full Text] [Related]  

  • 26. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drug awaiting FDA approval may reverse bone loss.
    Mayo Clin Health Lett; 2001 Nov; 19(11):4. PubMed ID: 11692627
    [No Abstract]   [Full Text] [Related]  

  • 29. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA approach to generics may be a mixed blessing.
    Sipkoff M
    Manag Care; 2008 Feb; 17(2):20-1. PubMed ID: 18361252
    [No Abstract]   [Full Text] [Related]  

  • 31. Pediatric drug development in anesthesiology: an FDA perspective.
    Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
    Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
    [No Abstract]   [Full Text] [Related]  

  • 32. A decade of the Fast Track programme.
    Reichert JM; Rochon SL; Zhang BD
    Nat Rev Drug Discov; 2008 Nov; 7(11):885-6. PubMed ID: 18948998
    [No Abstract]   [Full Text] [Related]  

  • 33. The drive to reform the FDA gains momentum.
    Gatty B
    Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
    [No Abstract]   [Full Text] [Related]  

  • 34. From laboratory to medicine cabinet.
    Caring; 1992 Nov; 11(11):16-20. PubMed ID: 10121248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advancing Alzheimer's disease drug review as a national priority.
    Perry DP
    Alzheimers Dement; 2009 Mar; 5(2):180-1. PubMed ID: 19328455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA revamps committee conflict-of-interest rules.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Oct; 98(19):1354-5. PubMed ID: 17018777
    [No Abstract]   [Full Text] [Related]  

  • 38. Should you let the FDA decide what drugs you pay for?
    Dutton G
    Bus Health; 1996 Oct; 14(10):65, 69-70, 73. PubMed ID: 10161492
    [No Abstract]   [Full Text] [Related]  

  • 39. Environmental assessments and findings of no significant impact--FDA. Notice.
    Fed Regist; 1998 May; 63(95):27300-3. PubMed ID: 10179346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The FDA Amendments Act: reauthorization of the FDA.
    von Eschenbach AC
    Food Drug Law J; 2008; 63(2):579-84. PubMed ID: 18561478
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.